weightloss.com.au
Head-to-head comparison

Compare Contrave vs. Ozempic

Contrave and Ozempic represent two fundamentally different approaches to weight loss medication in Australia. Contrave is a daily oral tablet combining naltrexone and bupropion that targets brain reward pathways, producing ~5-8% weight loss. Ozempic is a weekly GLP-1 injection that achieves ~15% weight loss but is only PBS-subsidised for diabetes.

Contrave logo
Contrave
Naltrexone/Bupropion ER
~5-8%
avg. weight loss
$150-200 private
per month
Ozempic logo
Ozempic
Semaglutide 0.25-1mg
~15%
avg. weight loss
$32 PBS / $134 private
per month

Compare Contrave vs Ozempic at a Glance

Drug class
Contrave
Opioid antagonist + NDRI combination
Ozempic
GLP-1 receptor agonist
How taken
Contrave
Daily oral tablets
Ozempic
Weekly injection
Avg. weight loss
Contrave
~5-8%
Ozempic
~15%
First approved
Contrave
2014 (FDA), 2019 (TGA)
Ozempic
2017 (FDA), 2019 (TGA)
AU cost/month
Contrave
$150-200 private
Ozempic
$32 PBS / $134 private
PBS status
Contrave
No
Ozempic
Yes (diabetes only)
Prescription needed?
Contrave
Yes
Ozempic
Yes
AU supply status
Contrave
No issues
Ozempic
Constrained (improving)

Compare Contrave vs Ozempic Cost in Australia

Contrave
$150–200
$150-200 private
per month
Ozempic
$32–134
$32 PBS / $134 private
per month (PBS: Yes (diabetes only))

Private prescription cost per month in AUD.

Compare Contrave vs Ozempic Weight Loss Efficacy

Contrave
~5-8%
avg. weight loss (3-9%)
Ozempic
~15%
avg. weight loss (10-17%)

Contrave Clinical Trials

COR-I

6.1% weight loss vs 1.3% placebo

56 weeksn=1,742

COR-II

6.4% weight loss maintained

56 weeks

COR-BMOD

9.3% with intensive behaviour modification

56 weeks

Ozempic Clinical Trials

SUSTAIN 1-12

5-7kg weight loss (diabetes population)

30-104 weeks

STEP 1 (higher dose)

14.9% body weight reduction

68 weeks

Clinical trial data at highest approved doses. Individual results vary.

Compare Contrave vs Ozempic Side Effects

Contrave

Very common

  • Nausea (32%)
  • Constipation (18%)
  • Headache (14%)

Common

  • Vomiting
  • Dizziness
  • Insomnia
  • Dry mouth
  • Diarrhoea

Serious (rare)

  • Seizures (contraindicated in seizure disorders)
  • Increased blood pressure
  • Hepatotoxicity
  • Suicidal thoughts (bupropion, young adults)
  • Cannot be used with opioids

Ozempic

Very common

  • Nausea (20-44%)
  • Diarrhoea (8-30%)
  • Vomiting

Common

  • Constipation
  • Abdominal pain
  • Headache
  • Fatigue
  • Injection site reactions

Serious (rare)

  • Pancreatitis
  • Gallbladder problems
  • Kidney injury
  • Thyroid tumours (animal studies)
  • Suicidal ideation (under investigation)

Compare How Contrave and Ozempic Work

Contrave

Opioid antagonist + NDRI combination

Targets two brain pathways. Naltrexone (opioid antagonist) blocks reward/craving pathways in the mesolimbic dopamine circuit. Bupropion (NDRI) acts on the hypothalamic appetite centre to reduce hunger. The combination addresses both biological hunger drive and reward-based food cravings.

Ozempic

GLP-1 receptor agonist

Mimics the natural hormone GLP-1. Slows gastric emptying, increases insulin production, reduces glucagon, and acts on appetite centres in the brain to reduce hunger. Once-weekly injection in abdomen, thigh, or upper arm.

Compare Contrave vs Ozempic Dosing Schedule

Contrave

Daily oral tablets

DosePeriodNote
1 tab morningWeek 1Starting dose
1 AM + 1 PMWeek 2Escalation
2 AM + 1 PMWeek 3Escalation
2 AM + 2 PMWeek 4+Maintenance (4 tablets/day)

Ozempic

Weekly subcutaneous injection

DosePeriodNote
0.25mgWeeks 1-4Starting dose
0.5mgWeeks 5-8Dose escalation
1mgWeek 9+Maintenance dose

Compare Contrave vs Ozempic Australian Regulatory Status

Contrave

TGA Status
Registered on ARTG for chronic weight management
PBS Listed
No PBS listing
Supply Status
No supply issues
Key Advantage
Only combination oral weight loss drug in AU; no injections needed
UK Name
Marketed as Mysimba in the UK

Ozempic

TGA Status
Registered on ARTG for type 2 diabetes
PBS Listed
Yes, for type 2 diabetes (Authority Required)
Off-label Use
Restricted since Oct 2024 for new weight loss prescriptions
Supply Status
Ongoing shortage since 2022; improving but not resolved
Compounding
Compounded versions banned from 1 October 2024

This website is for informational and research purposes only.

We are not medical professionals and nothing on this page constitutes medical advice, diagnosis, or treatment. Always consult a qualified doctor or specialist before making any decisions about medication.

The weight loss medication landscape in Australia is changing rapidly. Information on this page may become outdated without notice. Data sourced from the TGA, FDA, MHRA, NICE, PBAC, Australian Prescriber, Obesity Evidence Hub, and clinical trial publications. Last reviewed March 2026.